Opinion|Videos|August 22, 2024
Updated Data from EHA 2024: Transplant Ineligible NDMM
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
Multiple myeloma experts analyze recent developments in transplant-ineligible newly diagnosed multiple myeloma treatment, focusing on the latest updates presented at EHA 2024 and their potential impact on patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the updated data from the trials below impact transplant ineligible NDMM?
- MAIA
- BENEFIT
- IMROZ
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5